Highest-materiality recent filing
AMN Healthcare Q2 2026 revenue up 2% to $673M; adjusted EPS $0.77 (+158% YoY)
Revenue $673.2M (+2% YoY); gross profit $205.9M (+5%).
AMN Healthcare Q1 2026 revenue $1.38B, adjusted EBITDA $166M, adjusted EPS $2.10 (up 366% YoY)
GAAP diluted EPS $1.59; adjusted diluted EPS $2.10, up 366% vs Q1 2025.
AMN Healthcare shareholders approve 1.42M share increase to 2025 Equity Plan
All nine director nominees elected with 27.7M to 29.4M votes for.
AMN Healthcare Q4 2025 revenue $748M, GAAP loss ($0.20)/share; FY revenue down 8%
Q4 revenue $748.2M (+2% YoY); net loss ($7.7M); diluted EPS ($0.20).
AMN Healthcare director R. Jeffrey Harris to retire; Eric Palmer nominated to board
R. Jeffrey Harris will retire as director effective at the 2026 annual meeting and will not stand for re-election.
AMN Healthcare presents at J.P. Morgan Healthcare Conference; filing contains no new financials
CEO Cary Grace presents at J.P. Morgan Healthcare Conference on Jan 14, 2026.
AMN Healthcare adopts amended bylaws aligning with Delaware law and updating meeting procedures
Board approved amended bylaws effective Dec 11, 2025, aligning with Delaware law developments.
AMN Healthcare Q3 revenue down 8% to $635M; adjusted EPS falls 36%
GAAP net income $29.3M ($0.76 diluted EPS) vs $7.0M ($0.18) a year ago; adjusted EPS $0.39, down 36%.
AMN Healthcare issues $400M 6.5% notes due 2031, amends credit facility to redeem $500M 2027 notes
Issued $400M aggregate principal of 6.500% Senior Notes due Jan 15, 2031; interest payable semi-annually.
AMN Healthcare amends credit facility: maturity to Oct 2030, size cut to $450M
Maturity extended to October 2030 from February 2028; facility size reduced from $750M to $450M.
AMN Healthcare prices $400M 6.5% senior notes due 2031; to redeem $500M 4.625% notes due 2027
Issued $400M senior unsecured notes due 2031 at 6.500% interest, priced at 100% of face value.
AMN Healthcare Q2 revenue down 11% to $658M; GAAP loss of $3.02/share, adj EPS $0.30
Revenue $658.2M (-11% YoY); net loss $116.2M vs not meaningful in Q2 2024.
AMN Healthcare Q1 revenue $690M, GAAP loss $0.03/sh; adjusted EPS $0.45
Revenue $689.5M, down 16% YoY; gross profit $198.1M, down 23% YoY.
AMN Healthcare shareholders approve 2025 Equity Plan, elect directors
Shareholders approved the AMN Healthcare 2025 Equity Plan with 28,953,916 for, 849,838 against.
AMN Healthcare Q4 revenue $735M, GAAP loss of $4.90/share, adj EPS $0.75, FY revenue down 21%
Q4 2024 revenue $734.7M, down 10% YoY; full-year revenue $2,983.8M, down 21% YoY.
AMN Healthcare Chairman Doug Wheat retires; Mark Foletta named Chairman
Douglas D. Wheat retired from Board effective February 4, 2025, designated Chairman Emeritus.
Douglas D. Wheat will not stand for re-election at the 2025 annual meeting and will retire from the Board.
AMN Healthcare Q3 2024 revenue down 19%; GAAP EPS $0.18, adjusted EPS $0.61
Revenue $687.5M, down 19% YoY; net income $7.0M (-87%); GAAP EPS $0.18.
AMN Healthcare appoints Brian Scott as CFO/COO, effective Nov 21, 2024
Brian Scott returns to AMN as CFO/COO after serving as CFO/CAO from 2011-2021.
AMN Healthcare CFO Jeffrey Knudson to step down November 8; reaffirms Q3 2024 guidance
CFO Jeffrey Knudson will step down on November 8, 2024 to pursue an opportunity outside healthcare staffing.
AMN Healthcare Q2 2024 revenue $741M (-25% YoY); GAAP EPS $0.42, adjusted EPS $0.98
Revenue $740.7M, down 25% vs Q2 2023 $1,561.6M; gross profit $229.8M (-30% YoY).
AMN Healthcare elects James H. Hinton to Board effective July 22, 2024
Board expands from 8 to 9 members; Hinton appointed as independent director effective July 22, 2024.
AMN Healthcare Q1 revenue $821M (-27% YoY); GAAP EPS $0.45 (-78%), adjusted EPS $0.97 (-61%)
Revenue $820.9M, down 27% from $1.12B in Q1 2023.
AMN Healthcare shareholders elect all 8 directors, approve officer exculpation charter amendment
All eight director nominees elected; Douglas D. Wheat received most votes against at 1,453,289.
Director Martha H. Marsh to step down at AMN Healthcare 2024 annual meeting
Marsh will not stand for re-election; term ends at the 2024 annual meeting.
AMN Healthcare Q4 revenue $818M, down 27% YoY; GAAP EPS $0.33
Q4 2023 revenue $818.3M (-27% YoY); net income $12.5M (-85%); diluted EPS $0.33 (-83%)
AMN Healthcare Q3 revenue $853.5M, down 25% YoY; adjusted EPS $1.97, down 23%
Revenue of $853.5M decreased 25% from Q3 2022; net income $53.2M fell 42%.
AMN Healthcare agrees to buy MSDR for $300M; expects Q4 2023 close
Definitive agreement to acquire MSDR for $300 million cash; expected to close Q4 2023 subject to regulatory approvals.
AMN Healthcare Q2 revenue down 31% to $991M; GAAP EPS $1.55, adj EPS $2.38
Revenue of $991.3M, down 31% YoY; net income $60.9M, down 51%.
AMN Healthcare CLO Denise Jackson retiring; Whitney Laughlin named successor
Denise Jackson to retire as Chief Legal Officer and Corporate Secretary effective August 18, 2023, after 23 years at AMN.
AMN Healthcare shareholders elect all directors, approve say-on-pay, ratify KPMG, reject proposal
All 9 director nominees elected; votes ranged from 32.1M to 33.8M.
AMN Healthcare enters $200M accelerated share repurchase agreement with JPMorgan
Initial payment of $200M to JPMorgan; receives ~1.76M shares on May 10, 2023.
AMN Healthcare Q1 revenue fell 27% to $1.13B; GAAP EPS $2.02 down 35%, adj EPS $2.49 down 29%
Revenue $1,126.2M, down 27% YoY; net income $84.1M down 42%.
AMN Healthcare Q4 revenue down 17%, EPS down 22%; credit facility expanded to $750M
Q4 revenue $1.126B (-17% YoY); GAAP EPS $1.88 (-22%), adjusted EPS $2.48 (-16%).
AMN Healthcare amends bylaws on special meetings, proxy cards, advance notice
Board approved amendments clarifying beneficial holders may request special meetings.
AMN Healthcare Q3 2022 revenue $1.139B, adjusted EPS $2.57
Revenue of $1.139B, up 30% YoY; net income $92.4M, up 25%.
Cary Grace appointed CEO of AMN Healthcare, effective Nov 28, 2022
Susan Salka resigns as CEO and board member on Nov 27, 2022, after 17 years as CEO.
AMN Healthcare Q2 revenue $1.427B, GAAP EPS $2.77, adjusted EPS $3.31
Revenue $1,426.6M up 66% YoY; net income $123.8M up 85% YoY.
AMN Healthcare announces $250M increase to share repurchase program; total remaining ~$326M
Board authorized additional $250M to existing share repurchase program.
AMN Healthcare shareholders elect all directors, reject special meeting proposal
All 9 director nominees elected; highest vote for Sylvia Trent-Adams, lowest for Martha H. Marsh (36.9M for, 1.6M against).
AMN Healthcare Q1 2022 revenue $1.553B (+75% YoY); GAAP EPS $3.09 (+111% YoY)
Revenue $1.553B (+75% YoY); net income $146M (+107% YoY).
AMN Healthcare CEO Susan Salka to retire by end of 2022; search for successor begins
Salka, CEO for 17 years and with company for 32, will remain in role until successor is named.
AMN Healthcare Q4 2021 revenue $1.36B, up 116%; EPS $2.42 GAAP, $2.95 adj.
Q4 revenue $1.36B (+116% YoY); full-year revenue $3.98B (+66% YoY).
AMN Healthcare preliminary Q4 2021 revenue $1.35-1.36B, beat guidance; raises margin outlook
Preliminary Q4 revenue $1.35-1.36B, above prior guidance due to strong demand across segments.
AMN Healthcare expands board to nine, elects Jorge A. Caballero as independent director
Board increased from 8 to 9 members; Jorge A. Caballero elected effective Dec 14, 2021.
AMN Healthcare increases share repurchase authorization by $150M to $300M total
Board approved additional $150M share repurchase authorization, bringing total to $300M.
AMN Healthcare Q3 revenue $878M (+59% YoY), GAAP EPS $1.54, adjusted EPS $1.73
Revenue $877.8M, +59% YoY; net income $74.0M, +184% YoY.
AMN Healthcare appoints Jeffrey R. Knudson as CFO effective Nov 8, 2021
Jeffrey R. Knudson named CFO/CAO, reporting to CEO Susan Salka; starts Nov 2, assumes role Nov 8.
AMN Healthcare Q2 2021 revenue $857M (+41% YoY); GAAP EPS $1.39 (+196%)
Revenue $857.4M, up 41% YoY; net income $66.8M, up 199%.
On February 4, 2025, Douglas D. Wheat, the Chairman of the Board of Directors (the “Board”) of AMN Healthcare Services, Inc. (the “Company”) notified the Company of his decision to retire from the Board, effective immediately.
Mark G. Foletta was appointed to serve as Chairman of the Board.
the Board has appointed Mark G. Foletta, a member of the Board since 2012, to serve as Chairman of the Board, effective as of the completion of the 2025 Annual Meeting, subject to his re-election to the Board at the 2025 Annual Meeting.
Douglas D. Wheat, the Chairman of the Board of Directors (the “Board”) of AMN Healthcare Services, Inc. (the “Company”) notified the Company and the Board that he will not stand for re-election at the Company’s 2025 annual meeting of shareholders (the “2025 Annual Meeting”), at which time he will retire from the Board.
On October 3, 2024, AMN Healthcare Services, Inc. (“AMN” or the “Company”) announced that Brian Scott will join AMN as its Chief Financial Officer and Chief Operating Officer (“CFO/COO”) reporting to Cary Grace, AMN’s President and Chief Executive Officer.
the departure of Jeffrey Knudson from his role as the Company’s CFO, effective November 8, 2024, to pursue an opportunity with a private company outside of the healthcare industry.
On October 1, 2024, the Company announced that Jeffrey Knudson will step down from his role as Chief Financial Officer of the Company, effective November 8, 2024, to pursue an opportunity with a private company outside of the healthcare staffing industry.
voted to increase the size of the Board from eight to nine members, and to elect Mr. James H. Hinton as a new director to fill the vacancy created by such increase, with such appointment effective July 22, 2024.
Martha H. Marsh, a member of the board of directors (the "Board") of AMN Healthcare Services, Inc. (the "Company") since 2010, notified the Board of her decision not to stand for re-election at the Company’s 2024 annual meeting of stockholders (the "Annual Meeting").
Whitney M. Laughlin will succeed Ms. Jackson as Chief Legal Officer and Corporate Secretary.
On July 6, 2023, Denise L. Jackson notified AMN Healthcare Services, Inc. (the “Company”) of her intention to retire from her role as Chief Legal Officer and Corporate Secretary of the Company, effective August 18, 2023.
Cary Grace will join the Company on November 28, 2022, as its President and Chief Executive Officer reporting to the board of directors of the Company (the “Board”).
Max materiality 0.85 · Median 0.65 · Most common event earnings